News

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.
After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...
How Ozempic’s maker lost its grip on the obesity market it created
Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
Investor's Business Daily on MSN14h
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Verywell Health on MSN16h
Not an 'Easy Way Out': How GLP-1 Users Navigate the Stigma of Weight Loss Drugs
Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 medications to support her weight loss goal. After six months on Wegovy ...
Was Jim Cramer Right About Eli Lilly and Company (LLY)?
We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...